Bruker Gains 50.3% in a Year: What's Driving the Rally?
BRKR's rally is fueled by BSI NANO growth, AI-driven metrology demand and gains in preclinical imaging despite tariff pressures.
Zacks Investment Research6/19/2026Positive
BRKR
Bruker CorporationNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$8.71B
P/E Ratio
—
EPS
$-0.23
Beta
1.29
52W High
$64.48
52W Low
$28.39
50-Day MA
$50.82
200-Day MA
$43.53
Dividend Yield
0.34%
Profit Margin
-0.34%
Forward P/E
15.22
PEG Ratio
1.52
About Bruker Corporation
Bruker Corporation develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions in the United States, Europe, Asia Pacific, and internationally. The company is headquartered in Billerica, Massachusetts.
Fundamentals
| Revenue (TTM) | $3.46B |
| Gross Profit (TTM) | $1.65B |
| EBITDA | $488.70M |
| Operating Margin | 6.18% |
| Return on Equity | -0.43% |
| Return on Assets | 2.70% |
| Revenue/Share (TTM) | $22.76 |
| Book Value | $16.09 |
| Price-to-Book | 3.83 |
| Price-to-Sales (TTM) | 2.52 |
| EV/Revenue | 3.158 |
| EV/EBITDA | 35.64 |
| Quarterly Earnings Growth (YoY) | -81.80% |
| Quarterly Revenue Growth (YoY) | 2.70% |
| Shares Outstanding | $152.23M |
| Float | $103.57M |
| % Insiders | 26.95% |
| % Institutions | 92.76% |
Historical Volatility
HV 10-Day
49.62%
HV 20-Day
46.77%
HV 30-Day
65.90%
HV 60-Day
61.79%
HV Rank
83.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($54.67 target)
2
Strong Buy6
Buy4
Hold1
SellLatest News
The Healthcare M&A Wave
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Forbes6/17/2026Neutral
Bruker Corporation (BRKR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Bruker Corporation (BRKR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha6/8/2026Neutral
Bruker (BRKR) Up 37.1% Since Last Earnings Report: Can It Continue?
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research6/5/2026Positive
Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026
WASHINGTON--(BUSINESS WIRE)---- $BRKR #BRKR--At ASM Microbe 2026, Bruker Corporation's (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnostics, molecular testing, and NGS workflows, advancing clinical research, and faster, actionable infectious disease diagnostics. During the ASM 2026 meeting, Bruker showcases the expanded clinical capabilities of the MALDI Biotyper® CA System enabled by.
Business Wire6/4/2026Neutral
Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry
SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, sustainable fuels and advanced energy storage. The timsMRMS is an innovative platform that combines Trapped Ion Mobility Spectrometry (TIMS) with extreme-resolution Magnetic Resonance Mass Spectrometry (MRMS), to unravel the complex molecular makeup of challenging fossil fuels and green energy materials. It accomplishes this wit.
Business Wire6/2/2026Neutral
Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the unique timsMRMS system, bringing the power of trapped ion mobility separation to ultra-high-resolution magnetic resonance mass spectrometry (MRMS). A translational oncology research initiative by Prof. Stephan Singer at University Hospital Tübingen enables therapy selection, measuring more than 10,000 proteins in FFPE biopsies to reveal actionable tumor biology when precision genomics is inconclus.
Business Wire6/1/2026Neutral
BRKR Stock Up Post Q1 Earnings & Revenue Beat, Margins Down
Bruker beats Q1 earnings and revenue estimates as Europe growth and strong BSI bookings offset margin pressure and softer organic sales.
Zacks Investment Research5/7/2026Positive
Bruker Corporation (BRKR) Q1 2026 Earnings Call Transcript
Bruker Corporation (BRKR) Q1 2026 Earnings Call Transcript
Seeking Alpha5/7/2026Neutral
Bruker (BRKR) Surpasses Q1 Earnings and Revenue Estimates
Bruker (BRKR) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.47 per share a year ago.
Zacks Investment Research5/6/2026Positive
More HEALTHCARE Stocks
Data last updated: 7/9/2026